ArticleJCI insight2020
Role of in silico structural modeling in predicting immunogenic neoepitopes for cancer vaccine development.
Article in JCI insight, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- The current state and trends of immunotherapy research in lung cancer: a review and bibliometric analysis.Frontiers in oncology · 2024Pooled it
- Humoral immunity in pancreatic cancer: B-cell heterogeneity, regulatory networks, and therapeutic opportunities.Cancer metastasis reviews · 2026Review
- Recent advances in therapeutic cancer vaccines.Nature reviews. Cancer · 2025Review
- Exosome applications for the diagnosis and treatment of pancreatic ductal adenocarcinoma: An update (Review).Oncology reports · 2025Review
- BAFF overexpression in triple-negative breast cancer promotes tumor growth by inducing IL-10-secreting regulatory B cells that suppress anti-tumor T cell responses.Breast cancer research and treatment · 2025Article
- Cancer neoepitopes viewed through negative selection and peripheral tolerance: a new path to cancer vaccines.The Journal of clinical investigation · 2024Review
- Structural and physical features that distinguish tumor-controlling from inactive cancer neoepitopes.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Systems immunology spanning tumors, lymph nodes, and periphery.Cell reports methods · 2023Review
- Article
- Worth a Pound of Cure? Emerging Strategies and Challenges in Cancer Immunoprevention.Cancer prevention research (Philadelphia, Pa.) · 2023Review
- Cancer immune escape: the role of antigen presentation machinery.Journal of cancer research and clinical oncology · 2023Review
- Converging on a Cure: The Roads to Predictive Immunotherapy.Cancer discovery · 2023Review
- Current Trends in Neoantigen-Based Cancer Vaccines.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Lung cancer immunotherapy: progress, pitfalls, and promises.Molecular cancer · 2023Review
- Messenger RNA vaccines for cancer immunotherapy: progress promotes promise.The Journal of clinical investigation · 2022Review
- Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies.Vaccines · 2022Review
- Engineering neoantigen vaccines to improve cancer personalized immunotherapy.International journal of biological sciences · 2022Review
- Promoting the formation of Pi-stacking interaction to improve CTL cells activation between modified peptide and HLA.American journal of translational research · 2022Article
- Multiple-Allele MHC Class II Epitope Engineering by a Molecular Dynamics-Based Evolution Protocol.Frontiers in immunology · 2022Article
- Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope.Nature communications · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
Abstract
In prior studies, we delineated the landscape of neoantigens arising from nonsynonymous point mutations in a murine pancreatic cancer model, Panc02. We developed a peptide vaccine by targeting neoantigens predicted using a pipeline that incorporates the MHC binding algorithm NetMHC. The vaccine, when combined with immune checkpoint modulators, elicited a robust neoepitope-specific antitumor immune response and led to tumor clearance. However, only a small fraction of the predicted neoepitopes induced T cell immunity, similarly to that reported for neoantigen vaccines tested in clinical studies. While these studies have used binding affinities to MHC I as surrogates for T cell immunity, this approach does not include spatial information on the mutated residue that is crucial for TCR activation. Here, we investigate conformational alterations in and around the MHC binding groove induced by selected minimal neoepitopes, and we examine the influence of a given mutated residue as a function of its spatial position. We found that structural parameters, including the solvent-accessible surface area (SASA) of the neoepitope and the position and spatial configuration of the mutated residue within the sequence, can be used to improve the prediction of immunogenic neoepitopes for inclusion in cancer vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.